Company

AbbVie Reports $54.3 Billion in 2023 Revenues Amid Humira Erosion and Segment Variability

Policy / Regulatory

US Senate Puts Brakes on Bill Targeting China-Based CDMOs Amid Stock Market Reactions

CompanyDrug

Biotech Pharmaceutical Secures Approval for Nimotuzumab in Head and Neck Cancer Treatment

CompanyDrug

BMS Sees Mixed Results in 2023: Growth in New Products Offset by Loss of Exclusivity

Policy / RegulatoryR&D

China Reports Over 4.8 Million New Cancer Cases in 2022 Amid Rising Incidence and Mortality Rates

CompanyDeals

Johnson & Johnson’s Kenvue Partners with Tencent for Integrated Health Services in China

CompanyDrug

Chongqing Genrix Biopharmaceutical Gets NMPA Clearance for IL-4Rα mAb Candidate GR1802

CompanyDeals

Inmagene Biopharmaceuticals Secures Exclusive License for HutchMed’s Drug Candidates IMG-007 and IMG-004

CompanyLegal / IP

Luye Pharma’s Paliperidone Palmitate NDA Avoids Patent Lawsuit, Clears Path for FDA Approval

CompanyDeals

Matridx Bio Secures Series C+ Funding to Advance Infectious Pathogens Diagnostics

CompanyDeals

China Medical System Reclaims Rights to Velphoro from WinHealth in Greater China

CompanyDrug

Sichuan’s Ancocare Gets FDA Green Light for Phase I/III Study of Oncolytic Virus in Neuroblastoma